Genomics informatics — Data elements and their metadata for describing the microsatellite instability (MSI) information of clinical massive parallel DNA sequencing
Introduction: Massively parallel sequencing is a high-throughput analytical approach to nucleic acid sequencing that allows whole genomes, transcriptomes, and specific nucleic acid targets. These advanced technologies have been used in the clinical field, and clinical sequencing has been applied to realize personalized medicine and precision medicine. ISO/TS 20428[1] has been developed for clinical usage. In the field of cancer treatment, various treatment strategies were performed differently from traditional anti-cancer chemotherapies. One of those strategies is the control of human immune system that maintains the action to extract cancer cells. Recent outcomes of clinical trials show that this immune therapy is efficient for some patients who have a specific molecular character of their tumor mass, such as PD-L1 or CTLA4 surface protein expression[2]. As a result, these molecular characters are used as biomarkers for selecting patients. In colon cancer, according to several clinical trials, it is reported that the status of MSI (microsatellite instability) is regarded as a biomarker that drugs based on immuno-therapy are more efficient for the patient with MSI-H (high)[3]. The status of MSI can be calculated and reported by small nucleotide deletion on a specific region of human genome reference with NGS sequencing[4]. According to US FDA, four NGS sequencing products were approved for companion diagnostics. Among these products, three NGS sequencing provide MSI status and value on the
Scope: This document identifies data elements and metadata to represent the information about microsatellite instability (MSI) for reporting the value of the biomarker using clinical massive parallel DNA sequencing. This document covers information about the MSI test result and related data, such as used resources, data generation condition, and data processing information which are helpful to clinical diagnosis and research. This document is not intended — for defining experimental protocols or methods for calculating the value of microsatellite instability (MSI), — for the other biological species than human resource, or — for the Sanger sequencing methods.